Clearmind Medicine

Company Overview

Snapshot

Founded in January 2021, Clearmind Medicine operates with 1–10 employees and has raised a total of $16.21M across 6 funding rounds. The company went public on NASDAQ in November 2022, following its public listing on CSE in June 2022.

Business overview

Clearmind Medicine is a Health Tech & Life Sciences company focused on developing treatments for binge behavior and mental health conditions, including alcohol use disorder, binge eating, and depression. Its core product, MEAI, is designed to provide a euphoric alcohol-like experience while reducing the desire to consume alcoholic beverages, aiming to support individuals struggling with moderation. The company operates in the pharmaceutical and drug discovery sectors, targeting the healthcare and laboratory markets.

Strategic signal

In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. This milestone indicates significant progress in the clinical development of their proprietary psychedelic-based treatment, CMND-100, and provides a strong validation of its potential efficacy and safety. This signals to investors a positive trajectory for the company's lead therapeutic candidate and its commitment to addressing critical mental health challenges.

Company Intelligence Q&A

What was a significant recent development regarding Clearmind Medicine's clinical trials for Alcohol Use Disorder?

In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder, indicating progress in the development of its CMND-100 treatment.

When did Clearmind Medicine expand its intellectual property protection for MEAI in depression treatment?

In November 2025, Clearmind Medicine expanded its global IP protection for MEAI in depression treatment with a new patent filing in South Korea.

What was the outcome of Clearmind Medicine's Data and Safety Monitoring Board review for its CMND-100 clinical trial?

In November 2025, Clearmind Medicine's Data and Safety Monitoring Board unanimously approved the continuation of the Phase I/IIa clinical trial for CMND-100 following a positive interim safety review.

What was a key strategic appointment made by Clearmind Medicine in October 2025?

In October 2025, Clearmind Medicine appointed Mary-Elizabeth Gifford as Chief of Global Impact to advance US partnerships and governmental engagement.

What was a recent development in Clearmind Medicine's efforts to combat cocaine addiction?

In October 2025, Clearmind Medicine advanced its fight against cocaine addiction with the publication of a U.S. patent application for its non-hallucinogenic neuroplastogen MEAI therapy.